Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.
Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.
© 2023 LBNN - All rights reserved.